At present, the prognosis of HER2-positive advanced gastric cancer is extremely poor, and some patients fail to benefit from first-line Herceptin treatment, thus facing difficulties in choosing second-line drugs.
Case Report
Here, we report a 61-year-old male patient with HER2-positive advanced gastric cancer who is primarily resistant to Herceptin and has poor therapeutic effect.
Management & Outcome
Afterwards, the OncoVeeTM-MiniPDX-guided anticancer method was used to screen drugs for second-line treatment, which resulted in liquefaction and necrosis of the patient's lesions and improved liver function indicators, as well as rapid relief of the patient's clinical symptoms.
Discussion
In the treatment of the Herceptin-resistant patient with advanced gastric cancer, OncoVeeTM-MiniPDX method screened drugs and brought clinical benefits.
FerlayJSoerjomataramIDikshitR, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer2015; 136: E359–E386.
2.
Van CutsemESagaertXTopalB, et al.Gastric cancer. Lancet (London, England)2016; 388: 2654–2664.
3.
TorreLBrayFSiegelR, et al.Global cancer statistics, 2012. CA Cancer J Clin2015; 65: 87–108.
4.
GravalosCJimenoA. HER2 In gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol2008; 19: 1523–1529.
5.
AnEOckCKimT, et al.Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. Annals of oncology : official journal of the European Society for Medical Oncology2017; 28: 110–115.
6.
Van CutsemEBangYFeng-YiF, et al.HER2 Screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2015; 18: 476–484.
7.
HofmannMStossOShiD, et al.Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology2008; 52: 797–805.
8.
BangYVan CutsemEFeyereislovaA, et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England)2010; 376: 687–697.
GandaraDLaraPMackP. Patient-Derived Xenografts for investigation of acquired resistance in oncogene-driven cancers: building a better mousetrap. Journal of clinical oncology : official journal of the American Society of Clinical Oncology2015; 33: 2839–2840.
11.
ChapuyBChengHWatahikiA, et al.Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood2016; 127: 2203–2213.
12.
Bissig-ChoisatBKettlun-LeytonCLegrasX, et al.Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. J Hepatol2016; 65: 325–333.
13.
NicolleDFabreMSimon-ComaM, et al.Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management. Hepatology (Baltimore, Md)2016; 64: 1121–1135.
14.
PalleJRochandAPernotS, et al.Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: current knowledge and future perspectives. Drugs2020; 80: 401–415.
15.
BozzettiCNegriFLagrastaC, et al.Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer2011; 104: 1372–1376.
16.
ParkSParkYRyuM, et al.Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: results of GASTric cancer HER2 reassessment study 1 (GASTHER1). European journal of cancer (Oxford, England : 1990)2016; 53: 42–50.
17.
KimJFoxCPengS, et al.Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest2014; 124: 5145–5158.
18.
DeguchiYOkabeHOshimaN, et al.PTEN Loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2017; 20: 416–427.
19.
KimCLeeCChonH, et al.PTEN Loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. Oncotarget2017; 8: 113494–113501.
20.
HuangLMaJZhangS, et al.Durable clinical response to pyrotinib after resistance to prior anti-HER2 therapy for HER2-positive advanced gastric cancer: a case report. Front Oncol2019; 9: 1453.
21.
MinutiGCappuzzoFDuchnowskaR, et al.Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer2012; 107: 793–799.
22.
TakahashiNFurutaKTaniguchiH, et al.Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer. Oncotarget2016; 7: 4925–4938.
23.
KwakEAhronianLSiravegnaG, et al.Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer. Cancer Discov2015; 5: 1271–1281.
RovielloGAprileGD’AngeloA, et al. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?Gastric Cancer2021; 24: 765–779.
26.
VendittiJWesleyRPlowmanJ. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976–1982, and future directions. Adv Pharmacol Chemother1984; 20: 1–20.
27.
ChoiSYLinDGoutPW, et al. Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv Drug Deliv Rev2014; 79–80: 222–237.
28.
ZhangFWangWLongY, et al. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response. Cancer Commun (Lond)2018; 38: 60.
